TKT and central nervous system cancer: To more closely model glioma treatment in the clinical setting, we waited one week for orthotopically implanted U87-L-iRFP cells to grow in nude mice before injecting the mice with tk-VLPs intratumorally on days 7 and 18 for a total of two doses, in combination with GCV administration.